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Abstract
Regulation of transcription is a key process in cellular homeostasis. It depends on regulators
that either repress or stimulate the transcription of genes, therefore controlling different bio-
logical functions. The Nuclear Receptor Corepressor 1 (NCOR1) is one of those co-repres-
sors that regulate the transcription by facilitating the recruitment of HDAC1, 2, 3, 4, 5 and 7.
In our article, by using an in silico approach, we evaluate the mutational status of NCOR1 in
breast and lung tumors. We identified that NORC1 is mutated in more than 3% of breast
tumors and lung adenocarcinomas and linked this fact with detrimental outcome in some
subtypes, particularly in those that are hormone receptor negative. In addition to these find-
ings, as mutations in this gene are deleterious, we confirmed that high levels of this gene
were linked with good prognosis in the same tumor subtypes. Findings in the same direction
were identified in lung adenocarcinomas, with mutations associated with detrimental prog-
nosis and high expression with better outcome. In conclusion, hereby we describe the pres-
ence and prognostic role of mutations in the NCOR1 gene in hormone receptor negative
breast and lung adenocarcinomas, and we also confirm that NCOR1 is a tumor suppressor
gene. Further studies should be performed to explore therapeutic mechanisms to restore its
function.
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Introduction
Regulation of transcription is a key process in cellular homeostasis [1, 2]. It depends on regula-
tors that either repress or stimulate the transcription of genes, therefore controlling different
biological functions [1, 2]. In this context, modifications of the transcription process have been
associated with human disorders, such as neurological or inflammatory diseases or cancer,
among others [1, 2].
Activation of transcription is regulated at different levels, and epigenetic mechanisms play a
central role [1, 3]. Notably, epigenetic modifications on histones can impact on the transcrip-
tion of different genes, and its deregulation has been involved in the initiation and progression
of tumors [1].
Acetylation of histones is mediated by enzymes like histone acetyltransferases and deacety-
lase (HDAC), that can modify the conformation of the chromatin and therefore affect the tran-
scriptional activity [2].
The function of these enzymes depends, in many occasions, on the presence of co-repressors,
which can facilitate or repress the transcription of several genes [4]. The Nuclear Receptor Core-
pressor 1 (NCOR1) is one of those co-repressors that regulates the transcription by facilitating the
recruitment of HDAC1, 2, 3, 4, 5 and 7 [5]. Among all, HDAC3 is probably the principal responsi-
ble of its activity, as the catalytic activity of this enzyme requires interaction with NCOR [3, 6].
NCOR1 plays a central role in human biology, being involved in many process including
lipid metabolisms, cell fate, glucose homeostasis or neural stem cells [5]. Indeed, germline
mutations of NCOR produce embryonic lethality [7]. NCOR1 has also been involved in cancer
[5, 8, 9]. Mutations or deletions of this gene have been described in several solid tumors, such
as colorectal cancer, bladder cancer or hepatocarcinomas [5, 8, 9]. Indeed, it has been consid-
ered as a tumor suppressor gene as reduced levels of the gene promote tumor proliferation and
invasion [5].
In our article, we evaluate the mutational status of NCOR1 in breast and lung tumors,
focusing on genes involved in transcriptional regulation. We identified that NCOR1 is
mutated in more than 3% of breast tumors and lung adenocarcinomas and linked with detri-
mental outcome in some subtypes. In addition to these findings, as mutations at this gene are
deleterious, we confirmed that high levels of this gene were linked with good prognosis in
those tumor types.
Material and methods
Identification of high-frequency mutated genes
Breast Cancer METABRIC database, contained in cBioportal (http://www.cbioportal.org),
includes genomic information from 2509 breast cancer samples [10]. Then, we selected the
772 samples from patients diagnosed with Invasive Breast Carcinoma (S1 Table). We studied
the gene mutation profile and selected those genes presented in more than 2% of the patients.
The frequency of mutation was independently confirmed for all the four different breast can-
cer subtypes using TCGA database (n = 818).
NCOR1 frequency of mutation in lung adenocarcinoma and squamous cell lung carcinoma
(n = 230 and n = 178, respectively) was extracted from TCGA database contained at cBioPortal
(http://www.cbioportal.org).
Functional analysis
The selected mutated genes were analyzed using the biological functional enrichment analyses
tool Enrichr (http://www.amp.pharm.mssm.edu/Enrichr/). An adjusted p-value <0.05 was
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used to select the enriched gene-sets. This tool was also used to evaluate genes present in the
mutated NCOR1 signature.
Outcome analyses
The genotype-2-Outcome online tool (http://www.g-2-o.com) was used to evaluate the rela-
tionship between the presence of mutated NCOR1 and patient clinical outcome through the
development of a NCOR1 expression signature associated with all NCOR1 mutations [11].
This includes not only patients with NCOR1 mutation, but all patients who have a gene
expression signature similar to those with an NCOR1 mutation. This publicly available data-
base allowed assessment of clinical outcome (overall survival (OS)) for all the four breast can-
cer subtypes (All, Triple Negative Breast Cancer, Luminal A, Luminal B and HER2+) and
(relapse free survival (RFS)) for lung adenocarcinomas. In the analysis, the expression of genes
related to NCOR1 mutation was computed for each sample. Then, the upper quartile (25%
with higher expression) or the median across all patients was used to define two cohorts, and
each patient was assigned to those with higher expression or to those with lower expression,
based on the threshold defined for the upper quartile or the median value. The two cohorts
were compared using a Cox regression analysis.
KM Plotter Online Tool (http://www.kmplot.com) was used to investigate the relationship
between the NCOR1 expression and patient clinical outcome. This database allowed assess-
ment of overall survival (OS) and relapse-free survival (RFS) for all subtypes, basal-like, lumi-
nal A, luminal B, HER2+ and lung adenocarcinoma.
Patients were separated according to upper quartile or best cutoff values. For the latter, all
possible cutoff values between the lower and the upper quartiles are analyzed, and the one with
the lowest p value was used as a cutoff to separate the two patient cohorts. Patients above the
threshold were considered to have a “high” expression while patients below the threshold were
defined as those with “low” expression.
Evaluation of NCOR1 mutations
The information contained at cBioportal (http://www.cbioportal.org) was used to identify
NCOR1 mutations. The effect of each mutation on NCOR1 activity was investigated in SIFT
(http://sift.bii.a-star.edu.sg/) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) databases.
Assessment of NCOR1 association with therapy
We have searched GEO to identify breast cancer transcriptomic datasets with published treat-
ment and follow-up data as described previously [12, 13] to link gene expression levels to
patient’s response to the received therapy (Chemotherapy, Endocrine-therapy and Anti-HER2
therapy). Response was determined using relapse-free survival at five years: patients with a
relapse before five years were designated as non-responders, those without a relapse before five
years were designated as responders. Patients censored before five years follow-up were
excluded from the analysis. We performed Mann-Whitney analysis comparing responder and
non-responder patients in order to study the association of NCOR1 with therapy response.
Molecular subtypes were determined as described previously [14].
Results
Identification of mutations in transcriptional-regulated genes
We used public information from the METABRIC study (n = 772) to study genes mutated in
breast cancer patients (Fig 1A). We found a total of 172 altered genes, of which 69 were
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mutated in more than 2% of the patients. Next, we investigated their function using gene set
enrichment analyses and we focused on those involved in the regulation of transcription (Fig
1B). In addition, taking advantage of the online tool “genome 2 outcome”, which links gene
mutations with a transcriptomic signature associated with that mutation, we selected those
genes that predicted detrimental prognosis. With this approach, we found 9 mutated genes
associated with worse patient outcome (Fig 1A and S2 Table). Some of these genes have been
deeply explored in breast cancer, like TP53, RB1 or PiK3R1. However, others have been less
studied, like TAF1, KTM2D, RUNX1, EP300 or NCOR1 and NCOR2. We put our attention
on NCOR1, as it was the only one associated with detrimental outcome in a significant manner
in all breast cancer subtypes. Besides, little is known about its role in hormone receptor-nega-
tive breast tumors. Data obtained from the METABRIC study was corroborated with data
extracted from the TCGA database. As shown, NCOR1 was mutated in 3.76% of all breast
tumors, and in 3.65% of basal-like, 2% of Luminal A, 2.45% of Luminal B, and 3.33% of HER2
positive (Fig 1C).
Presence of NCOR1 mutations predict detrimental prognosis in triple
negative, HER2 positive and luminal B tumors
Using the NCOR1 mutational-transcriptomic signature as a read out of the mutation, we
explored the association of this signature with prognosis, overall survival (OS) specifically.
Mutations at NCOR1 were associated with detrimental outcome in all breast tumors (HR:0.63,
CI: 0.56–0.7; log rank p = 0), luminal B (HR:0.65, CI: 0.54–0.79; log rank p = 1.2e-05), basal
Fig 1. Whole genome mutation profiling and identification of regulation of transcription as an altered function in breast cancer. A. Flow chart of the study. B.
Functional analyses of the selected 69 mutated genes (Mutation frequency> 2.0%). C. NCOR1 frequency of mutation for the overall of the breast cancer cases (All
Breast Cancer), according to METABRIC (n = 2059), was confronted with data from the TCGA database (n = 818), which allows the estimation of the frequency of
mutation for each breast cancer subtype individually. This database was also used to extract the frequency of NCOR1 mutations in Lung Adenocarcinoma (LUAD)
(n = 230) and Lung Squamous Cells Carcinoma (LSCC) patients (n = 178).
https://doi.org/10.1371/journal.pone.0207776.g001
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(HR:0.58, CI: 0.45–0.76; log rank p = 3.3e-05) and HER2 positive tumors (HR:0.62, CI: 0.43–
0.90; log rank p = 0.012) (Fig 2A, 2B, 2C and 2D, respectively). The low prevalence of muta-
tions in the luminal A subtype limited the analyses between mutation and clinical outcome in
this subtype.
Functional analysis of the NCOR1 mutational-transcriptomic signature
Next, we explored which genes were included in the NCOR1 mutational signature and their
biological function. Genes down-regulated in NCOR1-mutated tumors include those involved
in lipid storage like DGAT2 and CD36, or cell surface receptor signaling including genes like
OXTR, SEMA6A or TNFRF25. Up-regulated genes comprised CXCL10, CYBB, SLC16A6 or
HNF4G (Fig 3A).
NCOR1 mutations and loss of function
As mutations of this gene have an impact on patient outcome, we aimed to analyze the biologi-
cal role of these mutations on the expression of the protein and its function. To do so, we used
the cancer genomics database cBioportal to identify NCOR1 mutations in each METABRIC
patient (Fig 3B). Missense and truncating mutations were the most frequent mutations identi-
fied with only one case of inframe mutations (Fig 3C). The functional impact of all these differ-
ent mutations, evaluated with two different databases (SIFT and PolyPhen-2), is displayed in
Fig 3D. As shown, most NCOR1 mutations are deleterious or damaging, therefore affecting
the functional role of the protein.
High NCOR1 transcriptomic levels are associated with good prognosis
If lack of activity of NCOR1 due to mutations is associated with detrimental outcome, elevated
levels of the gene would be linked with good prognosis. To explore this idea, we evaluated
NCOR1 at a transcriptomic level in relation with outcome in the different breast cancer sub-
types. As can be seen in Fig 4, high expression of NCOR1 is associated with better relapse free
survival in all breast cancer subtypes, including the luminal A subtype: all breast tumors (HR:
0.7, CI: 0.62–0.78; log rank p = 9e-11); luminal B (HR: 0.81, CI: 0.67–0.99; log rank p = 0.04);
basal (HR: 0.73, CI: 0.57–0.94; log rank p = 0.016); HER2 (HR:0.72, CI: 0.49–1.05; log rank
p = 0.085) and luminal A (HR:0.69, CI: 0.58–0.82; log rank p = 2e-05) (Fig 4A–4E).
To investigate the possibility that NCOR1 levels could be associated with response to ther-
apy, we correlated gene expression with clinical outcome based on the response to a selected
treatment. Expression levels of NCOR1 did not discriminate responders to anti-HER2 therapy
(n = 50) or chemotherapy (n = 476) in neither the HER2+ER- or triple negative subtypes (S3
Table). However, as it has been previously described (see discussion), expression of this gene
was able to predict response to anti-hormonal therapy (n = 907).
Presence of NCOR1 mutations, transcriptomic expression and association
with survival in lung cancers
To explore the option that NCOR1 also have a role in other cancer types, we explored if muta-
tions at this gene were linked with detrimental prognosis in lung cancer. Although no associa-
tion was observed for all the groups, a significant detrimental outcome (RFS) was identified
for the subgroup of lung adenocarcinomas (LUAD), particularly for the upper-quartile group
(HR: 0.72, CI: 0.51–1.00; log rank p = 0.046) (Fig 5A), compared with median cut-off (HR:
0.85, CI: 0.62–1.16; log rank p = 0.3) (Fig 5B). Of note, mutations in LUAD was reported in
3.91% of tumors (Fig 1C). Similarly, to breast cancer, we observed that high expression of the
NCOR1 in ER negative breast cancer and lung adenocarcinomas
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NCOR1 gene was associated with better overall survival and relapse free survival (HR: 0.38, CI:
0.3–0.48; log rank p<1e-16; HR: 0.26, CI: 0.16–0.41; log rank p = 3.9e-10; respectively) (Fig 5C
Fig 2. NCOR1 mutation-associated signature correlates with patients’ poor outcome. OS plots showing the association between survival and
NCOR1-mutation-related signature in all breast cancers (A), luminal B (B), basal (C) and HER2+ breast tumors (D) were obtained using Genotype-2-Outcome.
This tool found 58, 36, 11 and 7 patients carrying NCOR1 mutations in all breast cancer tumours, luminal B, basal and HER2 positive tumours, respectively. The
patients were separated in “high or low” expression groups according to the median value of the mean expression of NCOR1-mutation associated genes.
https://doi.org/10.1371/journal.pone.0207776.g002
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Fig 3. Functional analysis of the NCOR1 signature. A. Mutated NCOR1-associated up (blue) and downregulated (red) biological
process. NCOR1-associated genes within each function are indicated. B. Schema of NCOR1 mutations. C. Percentage of frequency
of Missense, Truncating and Inframe mutations. D. Percentage of Tolerated versus Deleterious and Benign versus Damaging
mutations.
https://doi.org/10.1371/journal.pone.0207776.g003
NCOR1 in ER negative breast cancer and lung adenocarcinomas
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and 5D), suggesting that this gene could behave as a tumor suppressor also in this tumor
subtype.
Discussion
In the present article, we explore mutations associated with genes involved in transcriptional
regulation that are linked with detrimental outcome. Among all the identified genes, we
focused on NCOR1, as this gene has not been described previously in hormone receptor nega-
tive breast tumors.
Deregulation of genes within transcription regulation has been involved in human patholo-
gies, including tumor initiation and progression [5,9]. In our study, we identify different
mutated genes within this function including some previously described and other that are
more novel. We focused on NCOR1 as this gene was associated with detrimental outcome in
all breast subtypes, and its association with survival in hormone receptor negative tumors has
not been evaluated before.
Some studies associate loss of expression of NCOR1 with cancer propagation and prolifera-
tion. Indeed, NCOR represses the expression of prometastatic genes like CXCR4, COX2,
CCR6 and CCR1 [15,16]. NCOR1 has been deeply studied in estrogen receptor positive breast
tumors. Loss of expression of NCOR1 has been associated with resistance to hormone therapy,
Fig 4. High NCOR1 expression levels correlates with better patients’ prognosis. Kaplan-Meier survival plots showing the association of NCOR1
expression levels with patients’ relapse free survival (RFS) for all breast cancers (n = 3951) (A), luminal B (n = 1149) (B), basal (n = 618) (C), HER2+
(n = 251) (D) and Luminal A (n = 1933) (E) breast tumors.
https://doi.org/10.1371/journal.pone.0207776.g004
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particularly tamoxifen as NCOR1 is a key corepressor for ERα [17,18]. Of note, this data is
also in line with our observation linking the presence of the gene with resistance to tamoxifen
or aromatase inhibitors. However, the role of NCOR1 mutations, particularly in tumors that
do not express the estrogen receptor has not been explored in the mentioned studies.
Fig 5. NCOR1 expression profile also predict outcome in Lung Adenocarcinoma patients (LUAD). A-B. Survival plots showing the correlation of
NCOR1-mutation related signature with RFS. The patients were separated in “high or low” using upper quartile expression (A) or median expression as
the cutoff value (B). C-D. Kaplan-Meier survival plots showing the association of NCOR1 expression levels with patients RFS (n = 720) and OS (n = 461).
https://doi.org/10.1371/journal.pone.0207776.g005
NCOR1 in ER negative breast cancer and lung adenocarcinomas
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Mutations in NCOR1 have been also described in other solid tumors, like colorectal cancer
or bladder cancer [8, 9]. In most occasions, these mutations were associated with a loss of func-
tion of the protein impairing their tumor suppressor capabilities [5, 8]. In our article, we
found that NCOR1 mutations in breast cancer are mainly missense and truncating, and pro-
duce a deleterious or damaging effect, leading to a nonfunctional protein. The lack of function
of this protein is therefore associated with the poor prognosis observed in those patients har-
boring the mutation. By contrast, we observed that tumors with elevated transcriptomic levels
of NCOR1 were linked with good prognosis as the protein levels are higher. Our findings were
also confirmed in lung adenocarcinomas, in which no data has been previously described.
A relevant observation was the fact that the expression of the gene was not associated with
clinical outcome based on the predicted response to anti-HER2 therapies or chemotherapies,
contrary to those treated with hormonotherapy. This confirms the role of NCOR1 as a tumor
suppressor gene in the estrogen receptor negative tumors.
Finally, it should be mentioned that the low number of mutations in luminal A tumors lim-
its their evaluation in relation with prognosis. We could anticipate that if a dysfunctional pro-
tein does exist, then, resistance to hormonotherapy could be present.
In conclusion, in the present work we describe the presence and prognostic role of muta-
tions at NCOR1 gene in hormone receptor negative breast and lung adenocarcinomas and we
also confirm that NCOR1 is a tumor suppressor gene. Further studies should be performed to
explore therapeutic mechanisms to restore its function.
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